{"id":"hydroxychloroquin","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"","severity":"common","organSystem":""},{"effect":"Anorexia","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Alcoholism","Anemia","Anemia due to enzyme deficiency","Deficiency of glucose-6-phosphate dehydrogenase","Disease of liver","Disorder of eye","Disorder of macula of retina","Neutropenic disorder","Porphyria","Psoriasis","Retinal disorder","Visual field defect","Visual impairment"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Cardiomyopathy","drugRate":"","severity":"serious"},{"effect":"Cardiac failure","drugRate":"","severity":"serious"},{"effect":"Ventricular tachycardia","drugRate":"","severity":"serious"},{"effect":"Torsades de pointes","drugRate":"","severity":"serious"},{"effect":"Retinopathy","drugRate":"","severity":"serious"},{"effect":"Aplastic anemia","drugRate":"","severity":"serious"},{"effect":"Stevens-Johnson syndrome","drugRate":"","severity":"serious"},{"effect":"Toxic epidermal necrolysis","drugRate":"","severity":"serious"},{"effect":"Fulminant hepatic failure","drugRate":"","severity":"serious"},{"effect":"Seizure","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["Hydroxychloroquine Sulfate; Plaquenil","Plaquenil"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"517ee47b-6abf-43cb-a4ca-c2e7827461a8","title":"HYDROXYCHLOROQUINE SULFATE TABLET [BRYANT RANCH PREPACK]"},"ecosystem":[],"mechanism":{"target":"Transmembrane protein 97, Alpha-1D adrenergic receptor, Alpha-2A adrenergic receptor"},"_scrapedAt":"2026-03-28T00:23:26.948Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Discoid lupus erythematosus","diseaseId":"discoid-lupus-erythematosus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Falciparum malaria","diseaseId":"falciparum-malaria","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Malaria Prevention","diseaseId":"malaria-prevention","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Ovale malaria","diseaseId":"ovale-malaria","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Plasmodium Falciparum Malaria Prevention","diseaseId":"plasmodium-falciparum-malaria-prevention","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Plasmodium Malariae Malaria Prevention","diseaseId":"plasmodium-malariae-malaria-prevention","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Plasmodium Ovale Malaria Prevention","diseaseId":"plasmodium-ovale-malaria-prevention","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Quartan malaria","diseaseId":"quartan-malaria","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rheumatoid arthritis","diseaseId":"rheumatoid-arthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Systemic lupus erythematosus","diseaseId":"systemic-lupus-erythematosus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Vivax malaria","diseaseId":"vivax-malaria","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01480154","phase":"PHASE1","title":"Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-11-23","conditions":"Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7","enrollment":62},{"nctId":"NCT07497282","phase":"PHASE2","title":"Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2026-03-26","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT01145196","phase":"","title":"Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene","status":"RECRUITING","sponsor":"National Eye Institute (NEI)","startDate":"2010-08-23","conditions":"Genotype, Retinal Disease","enrollment":320},{"nctId":"NCT05942911","phase":"PHASE2","title":"Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Incannex Healthcare Ltd","startDate":"2023-11-22","conditions":"Rheumatoid Arthritis","enrollment":20},{"nctId":"NCT07343635","phase":"NA","title":"The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea","status":"RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2026-02-01","conditions":"Erythematotelangiectatic Rosacea","enrollment":186},{"nctId":"NCT03822780","phase":"NA","title":"Hydroxychloroquin (HCQ) in chILD of Genetic Defect","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2017-07-01","conditions":"Surfactant Dysfunction","enrollment":25},{"nctId":"NCT04678648","phase":"PHASE1","title":"A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies","status":"RECRUITING","sponsor":"RasCal Therapeutics, Inc.","startDate":"2021-03-03","conditions":"Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer","enrollment":134},{"nctId":"NCT04532346","phase":"EARLY_PHASE1","title":"Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2024-09-01","conditions":"Interstitial Lung Disease, Surfactant Dysfunction","enrollment":60},{"nctId":"NCT07467252","phase":"PHASE2","title":"AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT","status":"NOT_YET_RECRUITING","sponsor":"Ministry of Health, Saudi Arabia","startDate":"2026-09","conditions":"Pulmonary Tuberculosis","enrollment":200},{"nctId":"NCT04527549","phase":"PHASE2","title":"Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-06-01","conditions":"Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","enrollment":5},{"nctId":"NCT07280741","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2025-12-02","conditions":"Autoimmune Rheumatic Diseases","enrollment":200},{"nctId":"NCT05016297","phase":"PHASE2","title":"Efficacy and Safety of Baricitinib in Sjogren's Syndrome","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2022-07-14","conditions":"Sjogren's Syndrome","enrollment":87},{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT07443436","phase":"PHASE2","title":"Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-10-01","conditions":"Interstitial Lung Disease","enrollment":30},{"nctId":"NCT04937907","phase":"PHASE2","title":"Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)","status":"COMPLETED","sponsor":"Shanghai Children's Hospital","startDate":"2021-09-08","conditions":"Alport Syndrome, X-Linked","enrollment":50},{"nctId":"NCT05799378","phase":"PHASE3","title":"Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2024-06-27","conditions":"Systemic Lupus Erythematosus","enrollment":330},{"nctId":"NCT05041907","phase":"PHASE2","title":"Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2021-09-30","conditions":"COVID-19","enrollment":3800},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":"Mild Cognitive Impairment, Dementia, Mild","enrollment":73},{"nctId":"NCT06915701","phase":"PHASE2, PHASE3","title":"\"Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis\"","status":"RECRUITING","sponsor":"University of Guadalajara","startDate":"2026-02-06","conditions":"Rheumatoid Arthritis","enrollment":46},{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT07409740","phase":"","title":"Optical Coherence Tomography Angiography Evaluation Of Patients Taking Hydroxychloroquine","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-02-01","conditions":"Hydroxychloroquine Retinopathy","enrollment":90},{"nctId":"NCT04345692","phase":"PHASE3","title":"A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients","status":"TERMINATED","sponsor":"Queen's Medical Center","startDate":"2020-03-26","conditions":"COVID-19","enrollment":17},{"nctId":"NCT02595346","phase":"PHASE2","title":"Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2016-05-17","conditions":"Antiphospholipid Syndrome (APS)","enrollment":25},{"nctId":"NCT06408298","phase":"EARLY_PHASE1","title":"HCQ in Resectable Localized Prostate Cancer","status":"RECRUITING","sponsor":"Lionel.D.Lewis, MD","startDate":"2026-01-06","conditions":"Resectable Localized Prostate Cancer","enrollment":20},{"nctId":"NCT03598595","phase":"PHASE1, PHASE2","title":"Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-28","conditions":"Recurrent Osteosarcoma, Refractory Osteosarcoma","enrollment":31},{"nctId":"NCT04201457","phase":"PHASE1, PHASE2","title":"A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2020-01-17","conditions":"Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1","enrollment":57},{"nctId":"NCT05306353","phase":"PHASE2","title":"CD40L Antagonism in Rheumatoid Arthritis (RA)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-07-25","conditions":"Rheumatoid Arthritis","enrollment":2},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT04524702","phase":"PHASE2","title":"Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2020-09-14","conditions":"Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":10},{"nctId":"NCT05842174","phase":"PHASE1, PHASE2","title":"Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-02-01","conditions":"Hepatocellular Carcinoma","enrollment":93},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT07294872","phase":"PHASE1","title":"A Study of TIL in Advanced Solid Tumors (CZ)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2026-05-08","conditions":"Solid Tumor, Adult","enrollment":30},{"nctId":"NCT03481881","phase":"","title":"Pharmacokinetics of Drugs Administered to Children","status":"RECRUITING","sponsor":"Duke University","startDate":"2013-08-14","conditions":"Pediatric ALL","enrollment":200},{"nctId":"NCT06776445","phase":"PHASE1","title":"Efficacy and Safety of Different Dose Regimens of Gabapentin for Treating Erythema/Flushing in Rosacea: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2024-01-05","conditions":"Rosacea, Rosacea Subtype 1 (Erythematotelangiectatic)","enrollment":50},{"nctId":"NCT05671497","phase":"PHASE2, PHASE3","title":"The Effect of Cilostazol on Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT06161363","phase":"","title":"Description of Compliance With Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2023-11-27","conditions":"Lupus Erythematosus","enrollment":102},{"nctId":"NCT06828328","phase":"EARLY_PHASE1","title":"A Study of GC203 TIL in PDCA (RJ)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2025-02-10","conditions":"Pancreatic Cancer, Pancratic Ductal Adenocarcinoma, Treatment Side Effects","enrollment":10},{"nctId":"NCT04960072","phase":"EARLY_PHASE1","title":"A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2021-06-30","conditions":"Gastrointestinal Tumor","enrollment":50},{"nctId":"NCT06971744","phase":"PHASE2","title":"Autophagy Maintenance (AUTOMAIN)","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2025-12-18","conditions":"Ovarian Cancer","enrollment":38},{"nctId":"NCT06488950","phase":"EARLY_PHASE1","title":"A Study of TIL in Advanced Solid Tumors (DFGD)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2023-04-01","conditions":"Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects","enrollment":30},{"nctId":"NCT04943913","phase":"EARLY_PHASE1","title":"Study of GC101 TIL in Brain Glioma (Soochow2)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2021-05-06","conditions":"Glioma","enrollment":50},{"nctId":"NCT04967833","phase":"EARLY_PHASE1","title":"A Study of GC101 TIL in Advanced Solid Tumors (TR)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2021-04-22","conditions":"Advanced Solid Tumors","enrollment":20},{"nctId":"NCT05098171","phase":"EARLY_PHASE1","title":"A Study of GC201 TIL in Advanced Gynecologic Tumors (10hospital)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2021-09-26","conditions":"Advanced Gynecologic Tumors, Signal Switch Receptor Modified TIL, Treatment Side Effects","enrollment":50},{"nctId":"NCT05142475","phase":"EARLY_PHASE1","title":"A Study of GC101 TIL in Advanced Breast Cancer (10hospital)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2021-11-19","conditions":"Breast Cancer, Treatment Side Effects, Advanced Breast Cancer","enrollment":50},{"nctId":"NCT05098197","phase":"EARLY_PHASE1","title":"A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2021-09-26","conditions":"Advanced Liver Cancers, Tumor Infiltrating Lymphocyte, Treatment Side Effects","enrollment":50},{"nctId":"NCT05098184","phase":"EARLY_PHASE1","title":"A Study of GC101 TIL in Advanced Melanoma (10hospital)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2021-09-26","conditions":"Advanced Melanoma, Tumor Infiltrating Lymphocyte, Treatment Side Effects","enrollment":50},{"nctId":"NCT05843188","phase":"PHASE2","title":"Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-08-09","conditions":"Metastatic Colorectal Cancer","enrollment":155},{"nctId":"NCT07265297","phase":"PHASE3","title":"Using Hydroxychloroquine (HCQ) to Treat Steatohepatitis","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-08-12","conditions":"Steatohepatitis, Nonalcoholic","enrollment":210},{"nctId":"NCT02615938","phase":"PHASE2","title":"Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD)","status":"TERMINATED","sponsor":"Matthias Griese","startDate":"2015-08-21","conditions":"Interstitial Lung Disease, Diffuse Parenchymal Lung Disease, Children´s Interstitial Lung Disease","enrollment":35},{"nctId":"NCT04702256","phase":"PHASE3","title":"Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-12-09","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus (SLE)","enrollment":196},{"nctId":"NCT04344379","phase":"PHASE3","title":"Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-17","conditions":"SARS-CoV-2 Infection","enrollment":122},{"nctId":"NCT06083688","phase":"PHASE4","title":"Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi","status":"ACTIVE_NOT_RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2024-10-14","conditions":"Malaria,Falciparum, Anemia in Children","enrollment":1000},{"nctId":"NCT07230028","phase":"PHASE4","title":"Doxycycline Boosted Therapy in Lyme Borreliosis: DoBo Study.","status":"NOT_YET_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2026-03-01","conditions":"Lyme Borreliosis, Nervous System","enrollment":50},{"nctId":"NCT04132505","phase":"PHASE1","title":"Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-22","conditions":"Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":39},{"nctId":"NCT04787991","phase":"PHASE1","title":"Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Cancer Insight, LLC","startDate":"2021-08-09","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":45},{"nctId":"NCT05576896","phase":"PHASE2","title":"Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2022-10-10","conditions":"Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV","enrollment":43},{"nctId":"NCT00977470","phase":"PHASE2","title":"Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2009-10","conditions":"Non-small Cell Lung Cancer","enrollment":76},{"nctId":"NCT05036226","phase":"PHASE1, PHASE2","title":"COAST Therapy in Advanced Solid Tumors and Prostate Cancer","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2022-03-03","conditions":"Prostate Cancer Recurrent, Solid Tumor, Adult","enrollment":76},{"nctId":"NCT07190534","phase":"","title":"The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)","status":"NOT_YET_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2025-11","conditions":"Frontal Fibrosing Alopecia, Cicatricial Alopecia","enrollment":50},{"nctId":"NCT04007562","phase":"","title":"Acute Rhabdomyolysis and Muscle Pain Associated With Mutations in the LPIN1 Gene - A Retrospective Study Describing the Safety and Efficacy of Hydroxychloroquine Sulfate Given on a Compassionate Basis to Patients Suffering From Lipin-1 Deficiency","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-11-04","conditions":"LIPIN1 Deficiency","enrollment":""},{"nctId":"NCT05221320","phase":"PHASE2","title":"Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies","status":"TERMINATED","sponsor":"BioMed Valley Discoveries, Inc","startDate":"2022-05-26","conditions":"Tumor, Solid, Gastrointestinal Cancer","enrollment":47},{"nctId":"NCT04333654","phase":"PHASE1","title":"Hydroxychloroquine in Outpatient Adults With COVID-19","status":"TERMINATED","sponsor":"Sanofi","startDate":"2020-04-12","conditions":"Coronavirus Infection","enrollment":8},{"nctId":"NCT06652113","phase":"NA","title":"Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-11-15","conditions":"Recurrent Pregnancy Loss, Euthyroid With Thyroid Antibodies","enrollment":796},{"nctId":"NCT05279027","phase":"EARLY_PHASE1","title":"Zr89 + PET Companion Trial","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2022-03-08","conditions":"Melanoma (Skin)","enrollment":6},{"nctId":"NCT01284725","phase":"PHASE3","title":"Weaning of Immunosuppression in Nephritis of Lupus","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2011-02-16","conditions":"Nephritis of Lupus","enrollment":100},{"nctId":"NCT03030118","phase":"PHASE2","title":"Study of Anti-Malarials in Incomplete Lupus Erythematosus","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2017-12-28","conditions":"Systemic Lupus Erythematosus","enrollment":187},{"nctId":"NCT05841758","phase":"PHASE4","title":"Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-07-30","conditions":"Sarcoidosis, Pulmonary","enrollment":140},{"nctId":"NCT04397328","phase":"PHASE3","title":"COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada","status":"WITHDRAWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2020-05-30","conditions":"COVID-19","enrollment":""},{"nctId":"NCT03037437","phase":"PHASE2","title":"Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-02-16","conditions":"Hepatocellular Cancer","enrollment":64},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT04669197","phase":"PHASE2","title":"Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"HonorHealth Research Institute","startDate":"2020-12-01","conditions":"Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma","enrollment":19},{"nctId":"NCT07013110","phase":"PHASE2","title":"An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis","status":"RECRUITING","sponsor":"Prof Salvatore Albani","startDate":"2025-06-18","conditions":"Rheumatoid Arthritis (RA), Rheumatology","enrollment":124},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT06035887","phase":"","title":"Novel ERG for Detection of Hydroxychloroquine Retinopathy","status":"RECRUITING","sponsor":"King's College Hospital NHS Trust","startDate":"2024-05-31","conditions":"Hydroxychloroquine Retinopathy","enrollment":140},{"nctId":"NCT01506973","phase":"PHASE1, PHASE2","title":"A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2011-12","conditions":"Advanced Adenocarcinoma, Metastatic Adenocarcinoma","enrollment":119},{"nctId":"NCT03377179","phase":"PHASE2","title":"A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2018-03-07","conditions":"Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar","enrollment":65},{"nctId":"NCT03032406","phase":"PHASE2","title":"CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2017-01-23","conditions":"Breast Cancer Stage IIB","enrollment":53},{"nctId":"NCT06676384","phase":"PHASE4","title":"Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?","status":"RECRUITING","sponsor":"Christian Medical College, Vellore, India","startDate":"2025-02-15","conditions":"IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis","enrollment":585},{"nctId":"NCT07061717","phase":"PHASE3","title":"Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-07-01","conditions":"Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer","enrollment":474},{"nctId":"NCT04464759","phase":"PHASE1, PHASE2","title":"A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma","status":"RECRUITING","sponsor":"Ravi Amaravadi, MD","startDate":"2020-10-21","conditions":"Melanoma","enrollment":94},{"nctId":"NCT04354649","phase":"PHASE2","title":"Immune-Mediated Pathophysiology And Clinical Triage Program","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2021-09-16","conditions":"Arthritis, Arthralgia","enrollment":46},{"nctId":"NCT02603146","phase":"PHASE2","title":"Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-04-27","conditions":"Healthy Participants, Rheumatoid Arthritis (RA) Prevention","enrollment":144},{"nctId":"NCT06319560","phase":"NA","title":"Hydroxychloroquine in Type 2 Diabetes During Pregnancy","status":"RECRUITING","sponsor":"National University of Malaysia","startDate":"2024-03-24","conditions":"Diabetes in Pregnancy, Type 2 Diabetes","enrollment":56},{"nctId":"NCT04335084","phase":"PHASE2","title":"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","status":"COMPLETED","sponsor":"ProgenaBiome","startDate":"2020-06-22","conditions":"COVID-19, Coronavirus Infection, Sars-CoV2","enrollment":254},{"nctId":"NCT06350630","phase":"PHASE2","title":"Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2025-06","conditions":"IgA Nephropathy","enrollment":334},{"nctId":"NCT03979651","phase":"NA","title":"MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2019-10-15","conditions":"Metastatic NRAS Melanoma","enrollment":29},{"nctId":"NCT04379492","phase":"PHASE2","title":"A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19","status":"WITHDRAWN","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-05-05","conditions":"COVID-19, COVID19, Sars-CoV2","enrollment":""},{"nctId":"NCT05998759","phase":"PHASE2","title":"Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2023-12-02","conditions":"Connective Tissue Diseases, Thrombocytopenia","enrollment":296},{"nctId":"NCT06949982","phase":"PHASE2","title":"Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes","status":"RECRUITING","sponsor":"Sergey Orlov, MD","startDate":"2025-03-17","conditions":"Metastatic Colorectal Cancer (mCRC), Colorectal Neoplasms","enrollment":60},{"nctId":"NCT06939582","phase":"PHASE1, PHASE2","title":"Hydroxychloroquine Sulfate Tablets for Radiation-induced Oral Mucositis","status":"RECRUITING","sponsor":"Xingchen Peng","startDate":"2024-12-22","conditions":"Radiation-induced Oral Mucositis","enrollment":158},{"nctId":"NCT06020378","phase":"","title":"Hydroxychloroquine May be Beneficial for Preeclampsia","status":"ACTIVE_NOT_RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-01-01","conditions":"Pre-Eclampsia","enrollment":462},{"nctId":"NCT05630989","phase":"","title":"A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy","status":"RECRUITING","sponsor":"Mandana Kamgar, MD","startDate":"2023-02-07","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":80},{"nctId":"NCT05365893","phase":"EARLY_PHASE1","title":"PHL Treatment in Pancreatic Cancer","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2021-10-20","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":20},{"nctId":"NCT03825289","phase":"PHASE1","title":"Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2019-01-18","conditions":"Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer","enrollment":25},{"nctId":"NCT05083780","phase":"PHASE1","title":"Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changhoon Yoo","startDate":"2021-11-30","conditions":"Pancreatic Cancer","enrollment":40},{"nctId":"NCT04011410","phase":"PHASE2","title":"Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer","status":"COMPLETED","sponsor":"Patrick Hensley","startDate":"2019-12-03","conditions":"Prostate Cancer Recurrent","enrollment":20},{"nctId":"NCT06887517","phase":"","title":"Chinese Rheumatism Biobank(CRB)","status":"RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2025-02-10","conditions":"Lupus Erythematosus, Systemic","enrollment":300},{"nctId":"NCT04523857","phase":"PHASE2","title":"ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-11-01","conditions":"Breast Cancer","enrollment":66},{"nctId":"NCT04735068","phase":"PHASE2","title":"Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-04-09","conditions":"Non-Small Cell Lung Cancer, KRAS Mutation-Related Tumors","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":26,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Hydroxychloroquin","genericName":"Hydroxychloroquin","companyName":"Children's Hospital of Fudan University","companyId":"children-s-hospital-of-fudan-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}